On the other hand, for retinitis pigmentosa associated with the protein deletion type pathology caused by RPE65 gene abnormalities, gene therapy supplementing the wild-type gene was approved by the FDA in 2017, and its effectiveness has been already reported [47]. Here, RPE65 is linked to retinitis pigmentosa.